[{"id":"karyopharm","kind":"company","name":"Karyopharm Therapeutics","route":"/companies/karyopharm/","commit":"f7782c9f5f","date":"2026-09-10","author":"Jude Gomila","message":"Sources: official-website links on a further thirty companies","file":"src/data/spikes/ovarian.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"Official website\", url: \"https://www.karyopharm.com\" }]"}]},{"id":"karyopharm","kind":"company","name":"Karyopharm Therapeutics","route":"/companies/karyopharm/","commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/sponsor-aliases.ts","type":"added","fields":[{"field":"id"},{"field":"label"},{"field":"kind"}]},{"id":"karyopharm","kind":"company","name":"Karyopharm Therapeutics","route":"/companies/karyopharm/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/spikes/ovarian.ts","type":"changed","fields":[{"field":"tldr","before":"\"Maker of selinexor, the first nuclear export inhibitor, approved in myeloma; its endometrial cancer bet failed in 2026.\"","after":"\"Karyopharm makes selinexor, the first nuclear export inhibitor, approved in myeloma; its endometrial cancer bet failed in 2026.\""}]},{"id":"karyopharm","kind":"company","name":"Karyopharm Therapeutics","route":"/companies/karyopharm/","commit":"afc6af185b","date":"2026-09-08","author":"Jude Gomila","message":"Spikes: ovarian, endometrial, cervical cancer deep dives (74 new entities with structured outcomes, dosing, toxicity, regulatory events, gui","file":"src/data/spikes/ovarian.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"hq"},{"field":"country"},{"field":"companyType"},{"field":"website"},{"field":"ticker"},{"field":"sections"},{"field":"tldr"},{"field":"summary"},{"field":"drugs"}]}]